Earnings on the Doorstep For Sangamo Therapeutics, Inc

(SGMO) by 9.22% based on its latest 2017Q2 regulatory filing with the SEC. The score helps determine if a company's stock is valuable or not. Zacks Investment Research raised shares of Sangamo Therapeutics from a "hold" rating to a "buy" rating and set a $12.00 price objective for the company in a research report on Friday, August 18th.

Depending on the earnings numbers reported, Sangamo Therapeutics, Inc. The recent change has given its price a 15.2% lead over SMA 50 and -2.74% deficit over its 52-week high. About 447,431 shares traded.

The market experts are predicting a 72.37% rally, based on the high target price ($76) for Micron Technology, Inc. shares that is likely to be hit in the 52 weeks. It has outperformed by 13.08% the S&P500. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company. The hedge fund run by Philippe Laffont held 12.57M shares of the consumer services company at the end of 2017Q2, valued at $492.98M, down from 12.66M at the end of the previous reported quarter. The stock rose 1.94% or $0.77 reaching $40.56. Given that liquidity is king in short-term, SGMO is a stock with 83.61 million shares outstanding that normally trades 9.1% of its float. These holdings make up 63.88% of the company's outstanding shares. Therefore 81% are positive.

According to Finviz reported data, The SMA20 of the stock is at -4.06%, SMA50 is -1.81 percent, while SMA200 is 4.19%. The firm has "Buy" rating by Jefferies given on Thursday, June 22. The company was downgraded on Wednesday, October 19 by PiperJaffray. The company's market capitalization is $218.93 million.

This article was originally published by and is the sole property of American Banking News. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest.

In terms of earnings per share, 5 analysts have a -0.22 EPS mean target for the quarter ending Dec-17, for the quarter ending Mar-18, 4 analysts have a -0.23 EPS mean target and for the quarter ending Mar-18 there are 5 estimates of -0.82 EPS. If the ratio is greater than 1, then that means there has been an increase in price over the month. Its up 0.79, from 0.8 in 2017Q1. It improved, as 13 investors sold SGMO shares while 31 reduced holdings. BlackRock Fund Advisors raised its position in Sangamo BioSciences by 5.7% in the third quarter. Fic Capital holds 3.48% or 960,338 shares in its portfolio. SGMO has a beta of 3.06 and RSI is 38.14. Altrinsic Global Advsrs Llc holds 0.18% or 580,000 shares. Sangamo Therapeutics earned a media sentiment score of 0.20 on Accern's scale. Meeder Asset Mngmt accumulated 592 shares. Frontier Capital Mngmt Ltd Company owns 495,028 shares. Bogle Investment Mgmt LP De holds 394,877 shares.

Shares of Sangamo BioSciences (NASDAQ:SGMO) traded up 1.64% during mid-day trading on Tuesday, reaching $3.10. Baldwin Brothers Inc Ma owns 1,500 shares. Its down 5.1% from 8.06 million shares, reported previously. Geode Cap Ltd Liability Com has 727,615 shares.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Wednesday, August 9th. Eam Invsts Lc has invested 0.16% of its portfolio in Sangamo Therapeutics Inc (NASDAQ:SGMO). Sangamo Biosciences had 17 analyst reports since August 8, 2015 according to SRatingsIntel. Investors may also use shareholder yield to gauge a baseline rate of return. The P/E ratio is one of the most common ratios used for figuring out whether a company is overvalued or undervalued. The rating was maintained by JP Morgan on Thursday, September 3 with "Buy". The stock of Sangamo Therapeutics Inc (NASDAQ:SGMO) has "Buy" rating given on Friday, October 13 by Jefferies. The stock of Sangamo Therapeutics Inc (NASDAQ:SGMO) has "Buy" rating given on Wednesday, September 2 by Jefferies. The rating was maintained by Wedbush with "Buy" on Wednesday, September 2. The company was maintained on Saturday, August 8 by JP Morgan. Piper Jaffray Companies set a $8.00 target price on Sangamo Therapeutics and gave the company a "hold" rating in a report on Thursday, August 10th. On Tuesday, November 1 the stock rating was downgraded by Wedbush to "Neutral".

Like this


10 November 2017
Teddy Bridgewater: 'It's Good To Be Back'
Zimmer likes just about everything he's seen from the quarterback since he returned to practice October 18. When Bridgewater is fully ready to come back, this will not be a quarterback controversy.

10 November 2017
BMO Capital Sticks to Their Hold Rating for Pacira Pharmaceuticals
The total amount of shares outstanding is 40.16 million, giving the company a market capitalization of about 1.65 billion. Looking at some more average volume numbers, the 20 day is 913020, and the 50 day average volume is noted as 706470.

10 November 2017
Chip Gaines Is Completely Unrecognizable - Why He Shaved His Head!
While fans love renovation guru Chip Gaines , many have been vocal about his long - wind-blown and sometimes man-bunned - locks. The couple didn't announce exactly how much money was donated but, obviously, it was enough to get Gaines to go totally bald.

10 November 2017
ICC approves investigation into crimes against humanity in Burundi
The alleged acts of violence have reportedly resulted in the displacement of 413,490 persons between April 2015 and May 2017. Other African nations have made similar complaints, with both Gambia and South Africa having threatened to leave.

10 November 2017
SunTrust Banks Weighs in on LHC Group's FY2017 Earnings (LHCG)
The Firm operates through four divisions: home health services, hospice services, community services and facility services. With 148,800 avg volume, 7 days are for Lhc Group (NASDAQ:LHCG)'s short sellers to cover LHCG's short positions.

10 November 2017
Psychologist: Christmas music may be bad for your mental health
The Tampa Bay Times reported Best Buy began playing holiday music on October 22, making the electronic store the first to stream the songs.

10 November 2017
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) To Release Earnings
TH Capital maintained the stock with "Buy" rating in Friday, December 18 report. (NASDAQ:LGND) rating on Friday, March 11. The stock of Infinity Pharmaceuticals Inc. (NASDAQ:AXGN) has "Buy" rating given on Tuesday, November 22 by Lake Street.

10 November 2017
Allison Transmission Holdings, Inc. (ALSN) Plans $0.15 Quarterly Dividend
ValuEngine raised shares of Allison Transmission Holdings from a hold rating to a buy rating in a report on Friday, September 1st. Chartwell Investment Partners LLC lifted its stake in shares of Allison Transmission Holdings by 48.4% during the third quarter.

10 November 2017
Seagate Technology PLC (NASDAQ:STX) Insider Buys 5000 Shares of Stock
Oregon Public Employees Retirement Fund owns 0.01% invested in Tripadvisor Inc (NASDAQ:TRIP) for 11,930 shares. Ironwood Inv Counsel Limited Liability has 0.08% invested in Welltower Inc (NYSE:HCN) for 6,559 shares.

10 November 2017
PDP Governor, David Umahi wishes Buhari will contest 2019 Presidential Election
On Thursday, Buhari inaugurated the armed forces council and ratified the National Defence Policy 2017 (Revised); Harmonised Terms and Conditions of Service Officers 2017.